



About us

AGORA Pharmaceuticals s.r.o. was founded in 2015 as a bio-tech company focused on the **development of novel drugs against neurodegenerative Alzheimer's disease**. Name AGORA originally comes from the ancient Greek marketplace representing a center for communication, where big ideas were born.

Following the legacy of its name, AGORA has focused on a wide range of solid, non-illusionary but existing, very realistic, sometimes neglected or unfinished assets or products to put them forward under the new leadership and innovative approaches. AGORA Pharmaceuticals is an international company, which cooperates with academia, recognized scientists, as well as other necessary stakeholders in the field of neurodegenerative disorders and across the world of science, medicine, finances and regulatory organs.

AGORA Pharmaceuticals (AGR) security token was created with fundraising purpose, to cover the costs for development of further clinical trial phases of AGORA drugs.

Why Alzheimer's disease

- currently there are around **50 million Alzheimer's patients**, but due to ever-increasing life expectancy it is estimated that the number of patients suffering from this disease will raise to **80 million by 2030 and 152 million by 2050**
- development of effective therapeutics against Alzheimer's disease is one of the **major challenges of the 21st century**
- current treatment is only symptomatic and provides a relief for up to 3 years; it does not cure the cause of the disease
- the costs associated with care for demented patients are expected to rise by **2050 as high as 8% of world GDP** unless an effective treatment is found
- Alzheimer's disease represents **major health, social and economic burden** for families, communities, societies and states worldwide.

Our approach

Complex solution for Alzheimer's disease therapy development from idea to real solution.

There are three different drug substances by now:

- **Agora 1** - combination of two drugs, that already exist on the market alone
- **Agora 2** - one substance, that has in its structure two active substances already known
- **Agora 3** - brand new substance, that has never been described before

Each of them has **different approach how to combat Alzheimer's disease**. Different Alzheimer's disease pathways are used as targets for our drug candidates to minimize the failure.

Our team



Jan Pavlik, M.D., MBA

CEO, Former Commercial Lead in Biogen Czech Republic;
Professional advisor in the field of health care



Prof. Kamil Kuca, M.A., Ph.D.

Founder; Rector of the University of Hradec Kralove, Czech Republic, important Czech scientist specializing in chemistry and toxicology



Prof. Jakub Hort, M.D., Ph.D., FEAN.

Founder; Neurologist; Head of the Centre for Cognitive Disorders at Motol Hospital, Czech Republic



Prof. Martin Valis, M.D., Ph.D., FEAN.

Founder; Neurologist; Head of the Neurological Clinic at Hospital Hradec Králové, Czech Republic



Julia Zajacova, M.Sc.

Founder; Director of FABA LTD., British venture capital company



Manfred Windisch, Ph.D.

Founder; Expert in pharmacology of diseases of the central nervous system with years of experience in Neurosciences and preclinical/clinical projects